Brief: Palatin Announces Publication Of Vyleesi (Bremelanotide) FMRI Study In Women With Hypoactive Sexual Desire Disorder
17/10/2022 13:02
Oct 17 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN ANNOUNCES PUBLICATION OF VYLEESI (BREMELANOTIDE)
FMRI
STUDY IN WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
* PALATIN TECHNOLOGIES INC - BREMELANOTIDE SIGNIFICANTLY
INCREASED
SEXUAL DESIRE FOR UP TO 24 HOURS POST ADMINISTRATION
Source text for Eikon: ID:nPn86hsbVa
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity